LifeStance (LFST) Files Form 144 for 2.47M-Share Sale on NASDAQ

Rhea-AI Filing Summary

LifeStance Health Group, Inc. (LFST) filed a Form 144 reporting a proposed sale of 2,471,741 shares of common stock through Morgan Stanley & Co. LLC with an aggregate market value of $13,372,118.81. The filing lists approximately 388,936,394 shares outstanding and an approximate sale date of 08/18/2025 on NASDAQ. The securities to be sold were originally acquired on 06/10/2021 in pre-IPO transactions, with 14,183,201 shares reported as acquired at that time. The filer certifies they are unaware of undisclosed material adverse information about the issuer.

Positive

• Detailed transaction disclosure including number of shares, aggregate market value, broker, exchange, and approximate sale date
• Acquisition history provided: securities were acquired on 06/10/2021 in pre-IPO transactions and amount acquired is reported
• Certification of no undisclosed material adverse information by the filer is included

Negative

• Planned sale of 2,471,741 shares is disclosed which could increase available shares in the market (aggregate value $13,372,118.81)
• No information on any trading plan dates is provided in the remarks to indicate a Rule 10b5-1 plan adoption date

Insights

Securities Analyst

TL;DR: Form 144 discloses a planned sale of 2.47M LFST shares valued at $13.37M; transaction details and broker are provided.

The filing gives clear transaction specifics: number of shares, aggregate market value, broker (Morgan Stanley & Co. LLC), exchange (NASDAQ) and an approximate sale date. The securities were acquired in a pre-IPO transaction on 06/10/2021 and a substantially larger block (14,183,201 shares) was originally acquired, indicating the filer still holds a meaningful position relative to the shares being offered.

Impact to the market depends on execution and demand; the Form 144 itself is a routine regulatory notice that enables transparent secondary sales by insiders or early holders.

Corporate Governance Expert

TL;DR: The notice documents an insider-related sale plan with standard certifications about material information.

The filing includes the required representation that the filer is not aware of undisclosed material adverse information and notes the pre-IPO origin of the holdings. It lists no recent sales in the past three months. From a governance perspective, the filing follows disclosure norms and identifies the broker and planned sale timing, which helps shareholders assess potential share supply from an insider or large pre-IPO holder.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley & Co. LLC 1585 Broadway New York NY 10036	2471741	13372118.81	388936394	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/10/2021	Pre-IPO Transactions	Issuer			14183201	06/10/2021	Equity interests in the Issuer were purchased pre-IPO

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does LifeStance Health Group (LFST) disclose in this Form 144?

The filing discloses a proposed sale of 2,471,741 common shares through Morgan Stanley & Co. LLC with an aggregate market value of $13,372,118.81 and an approximate sale date of 08/18/2025 on NASDAQ.

When were the shares being sold originally acquired?

The securities were acquired on 06/10/2021 in pre-IPO transactions, and the filing reports 14,183,201 shares were acquired on that date.

How many shares outstanding does the filing report for LFST?

The filing reports 388,936,394 shares outstanding for the issuer.

Who is the broker handling the proposed sale?

The broker named in the Form 144 is Morgan Stanley & Co. LLC, located at 1585 Broadway, New York, NY 10036.

Did the filer report any sales of issuer securities in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months.